Objective
The EUROMALVAC2 consortium will develop malaria vaccines inducing protective antibody responses to P.falciparum bloodstage antigens, moving leading vaccine candidates towards GMP-production and clinical trial whilst validating 2nd and 3rd generation candidates in its malaria vaccine R&D 'pipeline '. The major projects within the EUROMALVAC2 work programme involve; a. Optimisation of synthesis of lead candidate malaria vaccines based on merozoite surface protein 1 (MSPl) and the apical merozoite antigen 1 (AMAl). b. Production and testing of more parasitised erythrocyte membrane protein (PfEMP-l) based vaccines. c. Production and testing of new vaccine formulations based on the N-terminal Block 2 sequences of MSP1 and on other, less well characterised merozoite antigens. d. Development of a transmission blocking vaccine based on gametocyte antigen Pfs48/45. e. Strengthening of preclinical and clinical testing facilities.
Fields of science
Call for proposal
Data not availableFunding Scheme
CSC - Cost-sharing contractsCoordinator
EH9 3JT Edinburgh
United Kingdom
See on map
Participants (11)
000 Hamburg
See on map
HG3 1PY Harrogate
See on map
2288 GJ Rijswijk Zh
See on map
7180 Seneffe
See on map
75724 Paris
See on map
London
See on map
69210 St Germain Sur L'arbresle
See on map
NW7 1AA London
See on map
6500 HB Nijmegen
See on map
171 82 Solna
See on map
2200 Koepenhagen
See on map